Change in hospital utilisation ‐ not measured · chronic obstructive pulmonary disease (COPD) with depression
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depressive symptoms · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Adverse events (nausea, dizziness) · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Mental health and well‐being · people who smoke
1 finding from 1 review
Smoking cessation · people who smoke
4 findings from 1 review
Show 1 more finding
Frequency of attacks Per week (over 2 weeks) · primary Raynaud's phenomenon
1 finding from 1 review
Severity of attacks · primary Raynaud's phenomenon
1 finding from 1 review
Duration of attacks per day (minutes) · primary Raynaud's phenomenon
1 finding from 1 review
QoL · primary Raynaud's phenomenon
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects ‐ measured over 8 weeks · primary Raynaud's phenomenon
It is very uncertain whether selective serotonin reuptake inhibitors changes adverse events (over 4 weeks) compared with placebo (very low certainty).
1 finding from 1 review
RCS · primary Raynaud's phenomenon
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
> 50% reduction in depressive symptoms · people with epilepsy and depression
1 finding from 1 review
Depressive symptoms · people with epilepsy and depression
1 finding from 1 review
no estimate extracted
15 participants
Very low
Seizure frequency · people with epilepsy and depression
1 finding from 1 review
no estimate extracted
15 participants
Very low
Treatment withdrawal · people with epilepsy and depression
It is very uncertain whether selective serotonin reuptake inhibitors changes withdrawals compared with cognitive behavioural therapy (very low certainty).
1 finding from 1 review
RR 0.44 [0.05, 3.85]
15 participants
Very low
Cognitive function · people with epilepsy and depression
1 finding from 1 review
Post‐treatment quality of life (QOLIE‐31 score, which has a range of 0‐200, with higher score indicates better quality of life) ( · people with epilepsy and depression
1 finding from 1 review
no estimate extracted
15 participants
Very low
Adverse effects ‐ adverse event profile · people with epilepsy and depression
1 finding from 1 review
Abstinence from drug use · summary findings of female review
Acceptance and commitment therapy (ACT) showed no clear difference in abstinence from drug use at 6 months compared with waiting list control (low certainty).
1 finding from 1 review
ASI drug score at 6 months · summary findings of female review
1 finding from 1 review